AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19682376 — intervention group
Group type: EXPERIMENTAL
Intervention: NP 06‐1 (Phellodendron amurense bark and Citrus sinensis peel) 740 mg/day (two capsules of 370 mg each, twice daily)
Number of subjects: 80
Study 19682376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17258690 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 407
Study 17258690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 15307856 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 5241
Study 15307856 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 5241
Study 12385434 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of omeprazole, amoxicillin, and clarithromycin for 1 week
Number of subjects: 0
Study 12385434 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 1 week
Number of subjects: 0
Study 12385434 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized absorbance change
Number of subjects: 0
Study 12385434 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% decline in standardized absorbance after 1 year
Number of subjects: 0
Study 10627977 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive coronary bypass (last two periods)
Number of subjects: 27
Study 10627977 — intervention group
Group type: COMPARATOR
Intervention: Sternotomy on a beating heart (n=12, 62.6 ± 8.2)
Number of subjects: 27
Study 10627977 — intervention group
Group type: COMPARATOR
Intervention: Sternotomy under CPB (n=81, 63.0 ± 8.5)
Number of subjects: 27
Study 7593503 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle stimulating hormone (FSH)
Number of subjects: 232
Study 7593503 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG)
Number of subjects: 232
Study 2256497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed oxytocin (every 8 minutes)
Number of subjects: 106
Study 2256497 — intervention group
Group type: COMPARATOR
Intervention: Continuous oxytocin (intravenous infusion)
Number of subjects: 106
Study 2256497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 7001489 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg twice daily
Number of subjects: 26
Study 7001489 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 60 mg twice daily
Number of subjects: 26
Study 7001489 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 80 mg twice daily
Number of subjects: 26
Study 7001489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7001489 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (all dosages)
Number of subjects: 26
Study 6406090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 10
Study 29194182 — intervention group
Group type: EXPERIMENTAL
Intervention: Kicking with elastic resistance during warm-up
Number of subjects: 16
Study 26296610 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day high-fat overfeeding (HFO) (60 E% fat, +50% calories)
Number of subjects: 44
Study 24768938 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct assignment design with two interim analyses (DAD-2)
Number of subjects: 0
Study 24768938 — intervention group
Group type: COMPARATOR
Intervention: Balanced randomized design with two interim analyses (BRD-2)
Number of subjects: 0
Study 24768938 — intervention group
Group type: COMPARATOR
Intervention: Direct assignment design with one interim analysis (DAD-1)
Number of subjects: 0
Study 22624284 — intervention group
Group type: EXPERIMENTAL
Intervention: RoboLeader (intelligent agent) perfectly reliable
Number of subjects: 0
Study 22624284 — intervention group
Group type: EXPERIMENTAL
Intervention: RoboLeader (intelligent agent) false-alarm prone (60% reliability)
Number of subjects: 0
Study 22624284 — intervention group
Group type: EXPERIMENTAL
Intervention: RoboLeader (intelligent agent) miss prone (60% reliability)
Number of subjects: 0
Study 22624284 — intervention group
Group type: EXPERIMENTAL
Intervention: RoboLeader (intelligent agent) false-alarm prone (90% reliability)
Number of subjects: 0
Study 22624284 — intervention group
Group type: EXPERIMENTAL
Intervention: RoboLeader (intelligent agent) miss prone (90% reliability)
Number of subjects: 0
Study 22624284 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual density manipulation (presence or absence of friendly soldiers)
Number of subjects: 0
Study 22624284 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual differences (attentional control and video gaming experience)
Number of subjects: 0
Study 22624284 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial ability
Number of subjects: 0
Study 20668448 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 18613319 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 148
Study 18613319 — intervention group
Group type: COMPARATOR
Intervention: Control pamphlet
Number of subjects: 148
Study 16061831 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-GHRH (0.25, 0.5, 2 or 4 mg)
Number of subjects: 32
Study 16061831 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-GHRH
Number of subjects: 32
Study 16061831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12695732 — intervention group
Group type: EXPERIMENTAL
Intervention: Soteria treatment (minimal use of antipsychotic medication)
Number of subjects: 179
Study 12695732 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital treatment (control)
Number of subjects: 179
Study 10486417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 1518
Study 10486417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study 7492836 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1835731 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (alpha-IFN) at least 5 MU/m2 t.i.w. for a minimum of 3 months
Number of subjects: 0
Study 1835731 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (alpha-IFN) at a standard dose of 5 MU QD or 9 MU t.i.w. for at least 1 year
Number of subjects: 0
Study 1835731 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (alpha-IFN) therapy
Number of subjects: 0
Study 7044880 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(R)-15-methyl prostaglandin E2 (arbaprostil) 100 microgram capsules, taken four times a day for 28 days
Number of subjects: 173
Study 7044880 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules, taken four times a day for 28 days
Number of subjects: 173
Study 31260752 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic summarization system using algorithms to extract health-related features from sensor data.
Number of subjects: 110
Study 31260752 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic summarization system producing summaries of data leading to health alerts.
Number of subjects: 110
Study 29098261 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-implant anchorage
Number of subjects: 20
Study 29098261 — intervention group
Group type: COMPARATOR
Intervention: Traditional anchorage
Number of subjects: 20
Study 26207431 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA: Combined spinal-epidural anesthesia (CSE) with a PCEA of ropivacaine 0.1% + sufentanil 0.5 μg/mL for 24 hours after CS
Number of subjects: 199
Study 26207431 — intervention group
Group type: EXPERIMENTAL
Intervention: ED: CSE with an ED bolus of 3 mg morphine after CS
Number of subjects: 199
Study 26207431 — intervention group
Group type: EXPERIMENTAL
Intervention: IT: spinal anesthesia with an IT bolus of 0.1 mg morphine before CS
Number of subjects: 199
Study 24418597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (tailored counselling during face-to-face visits, weekly for the first four weeks, monthly to six months, and two monthly to 12 months)
Number of subjects: 163
Study 24418597 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine care relating to smoking cessation at local primary health care service)
Number of subjects: 163
Study 24418597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (compared to usual care)
Number of subjects: 163
Study 22133450 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Chronic Pain Management Program (self-directed, self-paced, 6 weeks)
Number of subjects: 162
Study 22133450 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (treatment as usual)
Number of subjects: 162
Study 19648310 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% diclofenac sodium gel (Voltaren Gel)
Number of subjects: 385
Study 19648310 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 385
Study 17450706 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education
Number of subjects: 343
Study 17450706 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted education
Number of subjects: 343
Study 17450706 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education with booster messages
Number of subjects: 343
Study 17450706 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted education with booster messages
Number of subjects: 343
Study 15228193 — intervention group
Group type: EXPERIMENTAL
Intervention: 844ins68 allele in the cystathionine beta-synthase gene
Number of subjects: 1087
Study 15228193 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneity among Jewish communities
Number of subjects: 1087
Study 15228193 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of 844ins68 allele
Number of subjects: 1087
Study 15228193 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of 844ins68 as an anthropogenetic marker
Number of subjects: 1087
Study 11452240 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 mL)
Number of subjects: 12
Study 11452240 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (cabernet sauvignon)
Number of subjects: 12
Study 11452240 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 9570605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (30 mg initial bolus, 6 mL)
Number of subjects: 42
Study 9570605 — intervention group
Group type: COMPARATOR
Intervention: 5% lidocaine (30 mg initial bolus, 0.6 mL)
Number of subjects: 42
Study 9570605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine
Number of subjects: 42
Study 9570605 — intervention group
Group type: COMPARATOR
Intervention: 5% lidocaine
Number of subjects: 42
Study 9570605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 7923311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial antibiotic infusion therapy (Group A)
Number of subjects: 14
Study 7923311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion therapy plus percutaneous drainage of the abscess (Group B)
Number of subjects: 14
Study 7923311 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics alone (Group C)
Number of subjects: 14
Study 3144165 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide (75 to 240 mg/day)
Number of subjects: 49
Study 30791874 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 49
Study 30791874 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Behaviour and Network Therapy
Number of subjects: 49
Study 28809654 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Caregiver Training Program (FCTP)
Number of subjects: 36
Study 28809654 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 36
Study 25847793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional PPD
Number of subjects: 30
Study 25847793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional MMR
Number of subjects: 30
Study 25847793 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 23932181 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) alone
Number of subjects: 182
Study 23932181 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) plus cabergoline (0.5mg for 8 days)
Number of subjects: 182
Study 21233775 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-flat orthosis
Number of subjects: 20
Study 21233775 — intervention group
Group type: COMPARATOR
Intervention: Contoured orthoses
Number of subjects: 20
Study 21233775 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 20
Study 21233775 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging
Number of subjects: 20
Study 21233775 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoses judged as comfortable as my shoe
Number of subjects: 20
Study 19922128 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day glatiramer acetate (GA)
Number of subjects: 366
Study 19922128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 17144568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish/n-3 polyunsaturated fatty acids
Number of subjects: 0
Study 17144568 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing intake of fish/n-3 polyunsaturated fatty acids
Number of subjects: 0
Study 15232656 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐SSP presentation
Number of subjects: 72
Study 15232656 — intervention group
Group type: COMPARATOR
Intervention: Transaxial section presentation
Number of subjects: 72
Study 15232656 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐SSP
Number of subjects: 72
Study 11743700 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal sensory testing
Number of subjects: 24
Study 11743700 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal neurological examination
Number of subjects: 24
Study 9487840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare sonic toothbrush
Number of subjects: 24
Study 9487840 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 24
Study 8437319 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (EPN)
Number of subjects: 86
Study 8437319 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual conservative therapy)
Number of subjects: 86
Study 3518048 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus tobramycin (150 mg/kg body weight/24 h ceftazidime + 10 mg/kg body weight/24 h tobramycin)
Number of subjects: 20
Study 3518048 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime alone (150 mg/kg body weight/24 h)
Number of subjects: 20
Study 30898322 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic EGCG (arm A)
Number of subjects: 83
Study 30898322 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic EGCG (arm B)
Number of subjects: 83
Study 30898322 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (arm C)
Number of subjects: 83
Study 30578206 — intervention group
Group type: EXPERIMENTAL
Intervention: E0302 50 mg intramuscular injection twice a week for 16 weeks
Number of subjects: 128
Study 30578206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 26228097 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action (DA)
Number of subjects: 1107
Study 26228097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1107
Study 24120303 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (risperidone or aripiprazole)
Number of subjects: 14
Study 24120303 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 14
Study 22969201 — intervention group
Group type: EXPERIMENTAL
Intervention: Faringel (10 mL)
Number of subjects: 40
Study 19958532 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH at 4 L/h for 60 min then 2 L/h
Number of subjects: 14
Study 19958532 — intervention group
Group type: COMPARATOR
Intervention: CVVH at 2 L/h for 60 min then 4 L/h
Number of subjects: 14
Study 17332197 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (60 to 90 seconds) with maternal administration of syntocinon
Number of subjects: 39
Study 17332197 — intervention group
Group type: COMPARATOR
Intervention: Conventional delivery (control group)
Number of subjects: 39
Study 15555219 — intervention group
Group type: COMPARATOR
Intervention: etoposide/cisplatin
Number of subjects: 402
Study 15555219 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin/cisplatin
Number of subjects: 402
Study 11464426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 453
Study 11464426 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 453
Study 7994616 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol (CPT) and sub-therapeutic doses of cyclosporine A (CsA) at 2mg/kg/d
Number of subjects: 0
Study 3051519 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirable sulfuric acid aerosol at concentrations of 0, 380, 1060, and 1520 micrograms/m3
Number of subjects: 42
Study 3051519 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirable sulfuric acid aerosol at concentrations of 1060 and 1520 micrograms/m3
Number of subjects: 42
Study 31952497 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-adolescent communication regarding sexual and reproductive health
Number of subjects: 1057
Study 31952497 — intervention group
Group type: COMPARATOR
Intervention: Discussions with friends/peers
Number of subjects: 1057
Study 31952497 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative insights from parents
Number of subjects: 1057
Study 30377862 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP/PALB < 17.7 (LCP) group
Number of subjects: 401
Study 30377862 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP/PALB ≥ 17.7 (HCP) group
Number of subjects: 401
Study 30377862 — intervention group
Group type: COMPARATOR
Intervention: CRP/PALB
Number of subjects: 401
Study 30377862 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP group
Number of subjects: 401
Study 28576734 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cancer Recovery (MBCR)
Number of subjects: 600
Study 28576734 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi/Qigong (TCQ)
Number of subjects: 600
Study 28576734 — intervention group
Group type: COMPARATOR
Intervention: Immediate intervention (either MBCR or TCQ)
Number of subjects: 600
Study 28576734 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 600
Study 28576734 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analyses
Number of subjects: 600
Study 28576734 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic measures
Number of subjects: 600
Study 25365723 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33 °C (TTM33)
Number of subjects: 920
Study 25365723 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36 °C (TTM36)
Number of subjects: 920
Study 25365723 — intervention group
Group type: EXPERIMENTAL
Intervention: High vasopressor group
Number of subjects: 920
Study 25365723 — intervention group
Group type: COMPARATOR
Intervention: Low vasopressor group
Number of subjects: 920
Study 25365723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure
Number of subjects: 920
Study 23446684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg/day
Number of subjects: 386
Study 23446684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 90 mg/day
Number of subjects: 386
Study 23446684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 23446684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine (combined 45 mg/day and 90 mg/day)
Number of subjects: 386
Study 21402327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice (experimental group)
Number of subjects: 47
Study 21402327 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (control group)
Number of subjects: 47
Study 19729520 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise
Number of subjects: 40
Study 19729520 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance exercise
Number of subjects: 40
Study 19729520 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise
Number of subjects: 40
Study 19729520 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 17014274 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback
Number of subjects: 217
Study 17014274 — intervention group
Group type: COMPARATOR
Intervention: No feedback (Control)
Number of subjects: 217
Study 12809962 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg IV
Number of subjects: 75
Study 12809962 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 20 microg/kg IV
Number of subjects: 75
Study 12809962 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 0.2 mg/kg IV
Number of subjects: 75
Study 12809962 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 75
Study 11072441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg nicotine gum
Number of subjects: 608
Study 11072441 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg nicotine gum
Number of subjects: 608
Study 11072441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 9212119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketorolac 10 mg every 6 h for up to 3 days
Number of subjects: 252
Study 9212119 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone 7.5 mg plus acetaminophen 750 mg every 6 h for up to 3 days
Number of subjects: 252
Study 9212119 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules followed by ketorolac 10 mg every 6 h for up to 3 days
Number of subjects: 252
Study 8190292 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) of the left motor cortex
Number of subjects: 10
Study 8190292 — intervention group
Group type: COMPARATOR
Intervention: No TMS (control condition)
Number of subjects: 10
Study 3067374 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 52